PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28418202-6	2017	A molecular docking study was performed to investigate the possible binding mode of compounds 11, 17, and 26 with the active sites of the COX-2 and 5-LOX enzymes, where they showed nearly the same binding pattern as that of celecoxib and meclofenamic acid, respectively.	Meclofenamic Acid	238-255	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	138-143
28418202-6	2017	A molecular docking study was performed to investigate the possible binding mode of compounds 11, 17, and 26 with the active sites of the COX-2 and 5-LOX enzymes, where they showed nearly the same binding pattern as that of celecoxib and meclofenamic acid, respectively.	Meclofenamic Acid	238-255	arachidonate 5-lipoxygenase	Homo sapiens	148-153
25775522-6	2015	We report that GnRH1 neurons are strongly and uniformly interconnected by electrical synapses that can drive spiking in connected cells and can be reversibly blocked by meclofenamic acid.	Meclofenamic Acid	169-186	progonadoliberin-1	Haplochromis burtoni	15-20
25143712-10	2014	However, expression of rOAT1 and rOAT3 recovered after administration of meclofenamate, which is associated with the inhibition of I/R-evoked elevation of prostaglandin E2.	Meclofenamic Acid	73-86	solute carrier family 22 member 8	Rattus norvegicus	33-38
25452335-0	2015	Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5.	Meclofenamic Acid	0-17	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	39-42
25452335-0	2015	Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5.	Meclofenamic Acid	0-17	glycoprotein M6A	Homo sapiens	60-63
25452335-0	2015	Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5.	Meclofenamic Acid	0-17	alkB homolog 5, RNA demethylase	Homo sapiens	69-75
25452335-3	2015	Here, we have identified meclofenamic acid (MA) as a highly selective inhibitor of FTO.	Meclofenamic Acid	25-42	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	83-86
24328991-5	2014	KEY RESULTS: The potency of known gap junction uncouplers to uncouple hCx43 was ranked (according to IC50 ) as phorbol ester>digoxin>meclofenamic acid>carbenoxolone>heptanol.	Meclofenamic Acid	139-156	gap junction protein alpha 1	Homo sapiens	70-75
25143712-10	2014	However, expression of rOAT1 and rOAT3 recovered after administration of meclofenamate, which is associated with the inhibition of I/R-evoked elevation of prostaglandin E2.	Meclofenamic Acid	73-86	solute carrier family 22 member 6	Rattus norvegicus	23-28
25143712-12	2014	Meclofenamate also prevents the prostaglandin E2-dependent downregulation of rOAT1 and rOAT3 expression.	Meclofenamic Acid	0-13	solute carrier family 22 member 6	Rattus norvegicus	77-82
25143712-12	2014	Meclofenamate also prevents the prostaglandin E2-dependent downregulation of rOAT1 and rOAT3 expression.	Meclofenamic Acid	0-13	solute carrier family 22 member 8	Rattus norvegicus	87-92
22937138-7	2012	To understand how other NSAIDs bind to AKR1C3, we have determined ten crystal structures of AKR1C3 complexes that cover three different classes of NSAID, N-phenylanthranilic acids (meclofenamic acid, mefenamic acid), arylpropionic acids (flurbiprofen, ibuprofen, naproxen), and indomethacin analogues (indomethacin, sulindac, zomepirac).	Meclofenamic Acid	181-198	aldo-keto reductase family 1 member C3	Homo sapiens	92-98
24460671-5	2014	Classic non-steroidal anti-inflammatory drugs such as meclofenamic acid and indomethacin inhibit both isoforms of cyclooxygenase non-selectively or with low selectivity, exerting their anti-inflammatory activity via inhibiting cyclooxygenase-2, and their deleterious side-effects by inhibiting cyclooxygenase-1.	Meclofenamic Acid	54-71	prostaglandin-endoperoxide synthase 2	Homo sapiens	227-243
24460671-5	2014	Classic non-steroidal anti-inflammatory drugs such as meclofenamic acid and indomethacin inhibit both isoforms of cyclooxygenase non-selectively or with low selectivity, exerting their anti-inflammatory activity via inhibiting cyclooxygenase-2, and their deleterious side-effects by inhibiting cyclooxygenase-1.	Meclofenamic Acid	54-71	prostaglandin-endoperoxide synthase 1	Homo sapiens	294-310
22476723-6	2012	Coupling was blocked by meclofenamic acid (MFA), an inhibitor of cx43-containing channels.	Meclofenamic Acid	24-41	gap junction alpha-1 protein	Cavia porcellus	65-69
22476723-6	2012	Coupling was blocked by meclofenamic acid (MFA), an inhibitor of cx43-containing channels.	Meclofenamic Acid	43-46	gap junction alpha-1 protein	Cavia porcellus	65-69
18163459-7	2008	Since activation of the PKG pathways by celecoxib, indomethacin, and meclofenamic acid in this cell culture system required high concentrations of these compounds, it remains to be determined whether activation of this pathway contributes to the in vivo antitumor effects of specific NSAIDs.	Meclofenamic Acid	69-86	protein kinase cGMP-dependent 1	Homo sapiens	24-27
16954818-7	2006	In all vessels of young animals COX inhibition with meclofenamate only partially blocked vasoconstriction to AngII, whereas contractions were completely abolished in the aorta and carotid artery of older mice (P < 0.05 vs untreated for both).	Meclofenamic Acid	52-65	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	109-114
17073578-7	2006	Nimesulide, meclofenamate, and piroxicam were more selective towards SULT1A1 inhibition, while sulindac and ibuprofen were more selective towards SULT1E1 inhibition.	Meclofenamic Acid	12-25	sulfotransferase family 1A member 1	Homo sapiens	69-76
17073578-9	2006	Kinetic studies determined the type of inhibition of SULT1A1 for three agents (meclofenamate, nimesulide, aspirin) to be non-competitive or partial non-competitive versus both substrate (p-nitrophenol) and cofactor (PAPS).	Meclofenamic Acid	79-92	sulfotransferase family 1A member 1	Homo sapiens	53-60
17073578-11	2006	The inhibition of SULT1A1 by meclofenamate, nimesulide, salicylate and aspirin may be clinically relevant based on ratio of inhibition constant to predicted in vivo inhibitor concentration ([I]/IC(50) > 1).	Meclofenamic Acid	29-42	sulfotransferase family 1A member 1	Homo sapiens	18-25
16290292-0	2006	QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors.	Meclofenamic Acid	17-34	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	58-63
16290292-4	2006	Presented herein is a series of 21 derivatives of meclofenamic acid with selective COX-2 inhibitory activity.	Meclofenamic Acid	50-67	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	83-88
16243311-7	2005	The cyclooxygenase inhibitor meclofenamate (10(-5) M) augmented the maximal response to endothelin-1 in control arteries, and reduced it in ischemic arteries.	Meclofenamic Acid	29-42	endothelin-1	Sus scrofa	88-100
15598972-6	2005	Extracellular application of meclofenamate (EC(50) = 25 microM) and diclofenac (EC(50) = 2.6 microM) resulted in the activation of KCNQ2/Q3 K(+) currents, heterologously expressed in Chinese hamster ovary cells.	Meclofenamic Acid	29-42	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	131-136
15894011-7	2005	This increase in CVR by endothelin-1 was not affected by L-NAME and was reversed by meclofenamate or L-NAME + meclofenamate.	Meclofenamic Acid	84-97	endothelin-1	Capra hircus	24-36
15894011-7	2005	This increase in CVR by endothelin-1 was not affected by L-NAME and was reversed by meclofenamate or L-NAME + meclofenamate.	Meclofenamic Acid	110-123	endothelin-1	Capra hircus	24-36
10493112-0	1999	Inhibition of hKv2.1, a major human neuronal voltage-gated K+ channel, by meclofenamic acid.	Meclofenamic Acid	74-91	potassium voltage-gated channel subfamily B member 1	Homo sapiens	14-20
11208767-17	2001	Finally, inhibition of both COX isoforms with meclofenamate, in dogs treated with L-NAME (n=6), completely prevented the vasodilator and excretory actions of BK.	Meclofenamic Acid	46-59	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	28-31
11208767-17	2001	Finally, inhibition of both COX isoforms with meclofenamate, in dogs treated with L-NAME (n=6), completely prevented the vasodilator and excretory actions of BK.	Meclofenamic Acid	46-59	kininogen 1	Canis lupus familiaris	158-160
10718119-4	2000	The IC50 for inhibition of HL-PST were 0.02 microM (mefenamic acid); 0.12 microM (tolfenamic acid); 0.28 microM (niflumic acid); 0.87 microM (meclofenamic acid) and 1.50 microM (flufenamic acid).	Meclofenamic Acid	142-159	sulfotransferase family 1A member 1	Homo sapiens	30-33
15598972-0	2005	Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.	Meclofenamic Acid	0-17	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	53-58
15598972-5	2005	Here, we show that meclofenamic acid (meclofenamate) and diclofenac, two related molecules previously used as anti-inflammatory drugs, act as novel KCNQ2/Q3 channel openers.	Meclofenamic Acid	19-36	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	148-153
15598972-5	2005	Here, we show that meclofenamic acid (meclofenamate) and diclofenac, two related molecules previously used as anti-inflammatory drugs, act as novel KCNQ2/Q3 channel openers.	Meclofenamic Acid	38-51	potassium voltage-gated channel subfamily KQT member 2	Cricetulus griseus	148-153
15249120-6	2004	Co-treatment with prostaglandin H synthase inhibitors (meclofenamic acid and indomethacin) abolished the cAMP and progesterone responses to both HDL and ApoAI.	Meclofenamic Acid	55-72	apolipoprotein A1	Homo sapiens	153-158
12548089-6	2003	Incubation of kidney slices with 1 microM Ang-(1-7) caused a 20% reduction in [125I]-Ang II binding (n = 8) in the cortical tubulointerstitium, which was prevented when Ang-(1-7)-treated slices were incubated in the presence of 5 microM meclofenamate (1 +/- 2% increase, n = 8; p < 0.05).	Meclofenamic Acid	237-250	angiogenin	Rattus norvegicus	42-45
12548089-13	2003	The reduction in Ang II binding by Ang-(1-7) was blocked by meclofenamate and [d-Ala7]-Ang-(1-7), suggesting that cyclooxygenase products released through activation of a novel receptor participate in this effect.	Meclofenamic Acid	60-73	angiotensinogen	Rattus norvegicus	17-23
12548089-13	2003	The reduction in Ang II binding by Ang-(1-7) was blocked by meclofenamate and [d-Ala7]-Ang-(1-7), suggesting that cyclooxygenase products released through activation of a novel receptor participate in this effect.	Meclofenamic Acid	60-73	angiogenin	Rattus norvegicus	17-20
12548089-13	2003	The reduction in Ang II binding by Ang-(1-7) was blocked by meclofenamate and [d-Ala7]-Ang-(1-7), suggesting that cyclooxygenase products released through activation of a novel receptor participate in this effect.	Meclofenamic Acid	60-73	angiogenin	Rattus norvegicus	35-38
12524153-5	2003	Inhibition of cyclooxygenase with meclofenamate (10(-5) M) reduced the contraction to vasopressin in basilar arteries from diabetic female rats and in renal arteries from diabetic male rats, but not in any other experimental group.	Meclofenamic Acid	34-47	arginine vasopressin	Rattus norvegicus	86-97
12409963-6	2002	Similarly, contractions to endothelin-1 were largely blocked by meclofenamate and were increased in the aorta of obese mice.	Meclofenamic Acid	64-77	endothelin 1	Mus musculus	27-39
11844663-0	2002	Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors.	Meclofenamic Acid	21-38	prostaglandin-endoperoxide synthase 2	Homo sapiens	52-68
11844663-1	2002	This paper describes SAR studies involved in the transformation of the NSAID meclofenamic acid into potent and selective cyclooxygenase-2 (COX-2) inhibitors via neutralization of the carboxylate moiety in this nonselective COX inhibitor.	Meclofenamic Acid	77-94	prostaglandin-endoperoxide synthase 2	Homo sapiens	121-137
11844663-1	2002	This paper describes SAR studies involved in the transformation of the NSAID meclofenamic acid into potent and selective cyclooxygenase-2 (COX-2) inhibitors via neutralization of the carboxylate moiety in this nonselective COX inhibitor.	Meclofenamic Acid	77-94	prostaglandin-endoperoxide synthase 2	Homo sapiens	139-144
10639181-3	2000	Derivatization of the carboxylate moiety in moderately selective COX-1 inhibitors, such as 5,8,11,14-eicosatetraynoic acid (ETYA) and arylacetic and fenamic acid NSAIDs, exemplified by indomethacin and meclofenamic acid, respectively, generated potent and selective COX-2 inhibitors.	Meclofenamic Acid	202-219	cytochrome c oxidase I, mitochondrial	Mus musculus	65-70
10639181-5	2000	Only the amide derivatives of ETYA and meclofenamic acid inhibit COX-2; the esters are either inactive or nonselective.	Meclofenamic Acid	39-56	prostaglandin-endoperoxide synthase 2	Mus musculus	65-70
10493112-2	1999	Meclofenamic acid inhibited hKv2.1 in a concentration-dependent manner whereas the other three fenamates had weaker or no effect on these channels at a concentration of 100 microM.	Meclofenamic Acid	0-17	potassium voltage-gated channel subfamily B member 1	Homo sapiens	28-34
10493112-3	1999	The estimated IC50 of meclofenamic acid was 56.0 microM for hKv2.1 compared an IC50 of 155.9 microM for another human neuronal K channel (hKv1.1).	Meclofenamic Acid	22-39	potassium voltage-gated channel subfamily B member 1	Homo sapiens	60-66
10493112-3	1999	The estimated IC50 of meclofenamic acid was 56.0 microM for hKv2.1 compared an IC50 of 155.9 microM for another human neuronal K channel (hKv1.1).	Meclofenamic Acid	22-39	potassium voltage-gated channel subfamily A member 1	Homo sapiens	138-144
10493112-6	1999	Moreover, the effect of meclofenamic acid on hKv2.1 channels was not voltage-dependent.	Meclofenamic Acid	24-41	potassium voltage-gated channel subfamily B member 1	Homo sapiens	45-51
10493112-8	1999	These results indicate that meclofenamic acid inhibits hKv2.1 more potently than hKv1.1 and it is likely that this compound acts directly on the channel proteins.	Meclofenamic Acid	28-45	potassium voltage-gated channel subfamily B member 1	Homo sapiens	55-61
10402214-3	1999	Indomethacin or meclofenamic acid decreased (p < or = 0.05) 270-day Brahman placental secretion of PGE and PGF2alpha by 98 and 60%, respectively.	Meclofenamic Acid	16-33	lipase F, gastric type	Bos taurus	102-105
10417353-10	1999	Only meclofenamic acid and hexoestrol were potent competitive inhibitors for 20alpha-HSD, yielding K(i) values of 18.9 and 14.3 microM respectively.	Meclofenamic Acid	5-22	aldo-keto reductase family 1, member C3	Rattus norvegicus	77-88
10402214-14	1999	Also, indomethacin and meclofenamic may affect enzymes converting PGH to PGE rather than acting only on cyclooxygenase because indomethacin and meclofenamic acid lowered PGE secretion by 270-day Brahman placentas more than they lowered PGF2alpha.	Meclofenamic Acid	144-161	lipase F, gastric type	Bos taurus	73-76
10402214-14	1999	Also, indomethacin and meclofenamic may affect enzymes converting PGH to PGE rather than acting only on cyclooxygenase because indomethacin and meclofenamic acid lowered PGE secretion by 270-day Brahman placentas more than they lowered PGF2alpha.	Meclofenamic Acid	144-161	lipase F, gastric type	Bos taurus	170-173
10402214-8	1999	Secretion of PGE by 200-day Brahman placentas was reduced (p < 0.05) by indomethacin 72 and 82% and by meclofenamic acid 72 and 96%, respectively, at 4 and 8 h when compared to controls.	Meclofenamic Acid	106-123	lipase F, gastric type	Bos taurus	13-16
9829404-9	1998	Nimesulide had the next highest selectivity for COX2 (38-fold), and tolfenamic acid and meclofenamic acid had 15-fold selectivity for COX2.	Meclofenamic Acid	88-105	cytochrome c oxidase subunit II	Canis lupus familiaris	134-138
9674634-3	1998	Meclofenamate infusion (5 microg x kg(-1) x min(-1)) during 4 consecutive days (n=8) elicited a continuous decrease (P<0.05) in renal blood flow and plasma renin activity and a transitory decrease in sodium excretion.	Meclofenamic Acid	0-13	renin	Canis lupus familiaris	159-164
9815120-2	1998	Substance P (1 microM) caused the release of PGE2, measured with enzyme immunoassay, from the isolated airway segments; PGE2 release was inhibited by the neurokinin (NK)1-receptor antagonist, RP-67580, by inhibition of cyclooxygenase with meclofenamate, and by removal of the epithelium.	Meclofenamic Acid	239-252	tachykinin receptor 1	Rattus norvegicus	154-179
9674634-7	1998	Only a transitory decrease in plasma renin activity was found during meclofenamate infusion in this group.	Meclofenamic Acid	69-82	renin	Canis lupus familiaris	37-42
9274806-10	1997	In contracted intrapulmonary bronchi that had been treated with compound 48/80, substance P and capsaicin caused relaxation responses that were inhibited markedly or were nearly abolished by the NK1 receptor antagonist, RP67580, by meclofenamate, and by denuding the epithelium.	Meclofenamic Acid	232-245	tachykinin receptor 1	Rattus norvegicus	195-207
9351974-6	1997	The decreases in the inhibitory potencies on hPGHS-2(R106E) by the carboxylate-containing NSAIDs flurbiprofen, indomethacin, meclofenamic acid, and diclofenac on hPGHS-2(R106E) were 965-, 48-, 5.5-, and 4.5-fold, respectively.	Meclofenamic Acid	125-142	prostaglandin-endoperoxide synthase 2	Homo sapiens	45-52
9124405-6	1997	The renal vasodilatation induced by ADM was attenuated by meclofenamate, as well as by renal denervation, although not significantly.	Meclofenamic Acid	58-71	adrenomedullin	Canis lupus familiaris	36-39
9392837-4	1997	Vasodilator responses to T-kinin and bradykinin were attenuated by the nitric oxide synthase inhibitor, N omega Nitro-L-arginine methyl ester (L-NAME), but were not altered by the cyclooxygenase inhibitor, sodium meclofenamate, or the K+ ATP channel antagonist, U37883A.	Meclofenamic Acid	206-226	kininogen 1	Homo sapiens	37-47
9063712-7	1997	Meclofenamate given into the anteroventral third ventricular region 30 min before starting the hypertonic saline infusion abolished the osmotic vasopressin response without significantly changing the responses of the other variables.	Meclofenamic Acid	0-13	arginine vasopressin	Rattus norvegicus	144-155
9044476-6	1997	VIP also caused suppression of the ANG II pressor response, and this VIP-induced suppressive effect was reduced when L-N omega-nitro-arginine or 3 x 10(-6) M meclofenamate was added to the perfusate.	Meclofenamic Acid	158-171	vasoactive intestinal peptide	Rattus norvegicus	0-3
9044476-6	1997	VIP also caused suppression of the ANG II pressor response, and this VIP-induced suppressive effect was reduced when L-N omega-nitro-arginine or 3 x 10(-6) M meclofenamate was added to the perfusate.	Meclofenamic Acid	158-171	angiotensinogen	Rattus norvegicus	35-41
9044476-6	1997	VIP also caused suppression of the ANG II pressor response, and this VIP-induced suppressive effect was reduced when L-N omega-nitro-arginine or 3 x 10(-6) M meclofenamate was added to the perfusate.	Meclofenamic Acid	158-171	vasoactive intestinal peptide	Rattus norvegicus	69-72
8794819-8	1996	Endothelin-1 progressively reduced glomerular hydraulic pressure in a dose-dependent fashion in the meclofenamic acid group.	Meclofenamic Acid	100-117	endothelin 1	Canis lupus familiaris	0-12
8915770-12	1996	Indomethacin (1 microM), flurbiprofen (1 microM), and meclofenamic acid (1 microM) completely abolished the stimulatory effect of TGF-beta 1 on PGE2 and 6-keto-PGF 1 alpha formation without affecting TGF-beta 1-induced stimulation of 45Ca release.	Meclofenamic Acid	54-71	transforming growth factor, beta 1	Mus musculus	130-140
8915770-12	1996	Indomethacin (1 microM), flurbiprofen (1 microM), and meclofenamic acid (1 microM) completely abolished the stimulatory effect of TGF-beta 1 on PGE2 and 6-keto-PGF 1 alpha formation without affecting TGF-beta 1-induced stimulation of 45Ca release.	Meclofenamic Acid	54-71	transforming growth factor, beta 1	Mus musculus	200-210
8887574-8	1996	Pretreatment with the LTD4 receptor antagonist, pranlukast (ONO-1078, SB 205312) (20 mg/kg, intragastrically), significantly inhibited both the bronchoconstriction and the eosinophilia at 24 h, whereas the cyclooxygenase inhibitor, meclofenamic acid (5 mg/kg, intragastrically), had no effect on either parameter.	Meclofenamic Acid	232-249	cysteinyl leukotriene receptor 1	Cavia porcellus	22-35
8794819-10	1996	At that rate, endothelin-1 reduced glomerular hydraulic pressure from 63.3 +/- 1.4 to 47.0 +/- 1.4 mm Hg in the meclofenamic acid group (P < .01), a more than 25% reduction, whereas at the same dose, endothelin-1 reduced glomerular hydraulic pressure only less than 2% in the L-NAME group.	Meclofenamic Acid	112-129	endothelin 1	Canis lupus familiaris	14-26
8794819-10	1996	At that rate, endothelin-1 reduced glomerular hydraulic pressure from 63.3 +/- 1.4 to 47.0 +/- 1.4 mm Hg in the meclofenamic acid group (P < .01), a more than 25% reduction, whereas at the same dose, endothelin-1 reduced glomerular hydraulic pressure only less than 2% in the L-NAME group.	Meclofenamic Acid	112-129	endothelin 1	Canis lupus familiaris	203-215
8967523-4	1996	COX-2 expression induced by acute hypoxia was enhanced by an inhibitor of nitric oxide synthase, N(G)-nitro-L-arginine methyl ester, and was suppressed by sodium nitroprusside, meclofenamate, and H-7 (an inhibitor of protein kinase A and C).	Meclofenamic Acid	177-190	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	0-5
8891757-5	1996	Four non-steroidal antiinflammatory drugs, indomethacin, flurbiprofen, naproxen and meclofenamic acid, inhibited basal, IL-1 beta- and TNF-alpha-stimulated PGE2 formation in the MG-63 cells without affecting IL-1 beta- or TNF-alpha-induced inhibition of osteocalcin and type I collagen formation.	Meclofenamic Acid	84-101	interleukin 1 beta	Homo sapiens	120-129
8891757-5	1996	Four non-steroidal antiinflammatory drugs, indomethacin, flurbiprofen, naproxen and meclofenamic acid, inhibited basal, IL-1 beta- and TNF-alpha-stimulated PGE2 formation in the MG-63 cells without affecting IL-1 beta- or TNF-alpha-induced inhibition of osteocalcin and type I collagen formation.	Meclofenamic Acid	84-101	tumor necrosis factor	Homo sapiens	135-144
8891757-5	1996	Four non-steroidal antiinflammatory drugs, indomethacin, flurbiprofen, naproxen and meclofenamic acid, inhibited basal, IL-1 beta- and TNF-alpha-stimulated PGE2 formation in the MG-63 cells without affecting IL-1 beta- or TNF-alpha-induced inhibition of osteocalcin and type I collagen formation.	Meclofenamic Acid	84-101	interleukin 1 beta	Homo sapiens	208-217
8891757-5	1996	Four non-steroidal antiinflammatory drugs, indomethacin, flurbiprofen, naproxen and meclofenamic acid, inhibited basal, IL-1 beta- and TNF-alpha-stimulated PGE2 formation in the MG-63 cells without affecting IL-1 beta- or TNF-alpha-induced inhibition of osteocalcin and type I collagen formation.	Meclofenamic Acid	84-101	tumor necrosis factor	Homo sapiens	222-231
8967523-4	1996	COX-2 expression induced by acute hypoxia was enhanced by an inhibitor of nitric oxide synthase, N(G)-nitro-L-arginine methyl ester, and was suppressed by sodium nitroprusside, meclofenamate, and H-7 (an inhibitor of protein kinase A and C).	Meclofenamic Acid	177-190	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	217-239
8578896-4	1995	Initially, an intravenous administration of sodium meclofenamate (2.2 mg/kg bwt) was given; the obtained kinetic results were in agreement with data from other authors.	Meclofenamic Acid	44-64	BWT	Ovis aries	76-79
8750709-3	1995	The response to endothelin-1 was also recorded in veins pretreated with the nitric oxide synthesis inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME, 10(-4) M), or the cyclooxygenase inhibitor, meclofenamate (10(-5) M), and in veins without endothelium or placed in medium without Ca2+ but with EDTA (0.1 mM).	Meclofenamic Acid	198-211	endothelin 1	Canis lupus familiaris	16-28
7503103-10	1995	Similarly, meclofenamate, another prostaglandin inhibitor, attenuated (P < 0.001) angiotensin II-induced MA.	Meclofenamic Acid	11-24	angiotensinogen	Homo sapiens	85-99
7748188-8	1995	In this paper, we report that meclofenamic acid inhibited myeloperoxidase-dependent hydroxyl radical generation through scavenging of hypochlorous acid and not by direct inhibition of myeloperoxidase.	Meclofenamic Acid	30-47	myeloperoxidase	Homo sapiens	58-73
7675125-8	1995	The inhibition of prostaglandin synthesis (indomethacin or meclofenamate) prevented renin hypersecretion in response to (-)-ozolinone and modified its salidiuretic effects but had no effect on the vascular response.	Meclofenamic Acid	59-72	renin	Canis lupus familiaris	84-89
8578896-5	1995	Oral administrations (20 mg/kg bwt) of sodium meclofenamate and meclofenamic acid were then given.	Meclofenamic Acid	39-59	BWT	Ovis aries	31-34
7846106-6	1994	Cyclooxygenase inhibition by either indomethacin or meclofenamate (10(-6) M) did not influence ACh release.	Meclofenamic Acid	52-65	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	0-14
7864817-5	1995	NS-398, flurbiprofen, meclofenamic acid and indomethacin are time-dependent, irreversible inhibitors of hCox-2.	Meclofenamic Acid	22-39	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	104-110
7864817-8	1995	Flurbiprofen, meclofenamic acid and indomethacin are also time-dependent inhibitors of hCox-1 and hence show little selectivity for one isoform over the other.	Meclofenamic Acid	14-31	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	87-93
7700000-4	1994	Inhibition of prostaglandin (PG) formation by meclofenamate or EDRF synthesis by L-NAME markedly attenuated the increase of renin mRNA levels in response to clipping, and a combination of PG/EDRF inhibition almost abolished the increase of renin mRNA levels.	Meclofenamic Acid	46-59	renin	Rattus norvegicus	124-129
7853791-5	1994	Renal renin mRNA levels in the clipped kidneys increased 4.8-, 2.6-, 2.5- and 1.8-fold in the clipped kidneys in vehicle, meclofenamate, L-NAME and meclofenamate/L-NAME injected animals, respectively.	Meclofenamic Acid	122-135	renin	Rattus norvegicus	6-11
7853791-5	1994	Renal renin mRNA levels in the clipped kidneys increased 4.8-, 2.6-, 2.5- and 1.8-fold in the clipped kidneys in vehicle, meclofenamate, L-NAME and meclofenamate/L-NAME injected animals, respectively.	Meclofenamic Acid	148-161	renin	Rattus norvegicus	6-11
7811298-4	1994	We found that meclofenamic acid and flufenamic acid stimulated myoglobin-dependent lipid peroxidation, but only in the presence of H2O2.	Meclofenamic Acid	14-31	myoglobin	Homo sapiens	63-72
7811298-6	1994	Phenylbutazone, meclofenamic acid and flufenamic acid could also cause damage to proteins (as measured by inactivation of alpha 1-antiproteinase) in the presence of myoglobin and H2O2.	Meclofenamic Acid	16-33	serpin family A member 1	Homo sapiens	122-144
7811298-6	1994	Phenylbutazone, meclofenamic acid and flufenamic acid could also cause damage to proteins (as measured by inactivation of alpha 1-antiproteinase) in the presence of myoglobin and H2O2.	Meclofenamic Acid	16-33	myoglobin	Homo sapiens	165-174
7955144-5	1994	Pulmonary vasodilator responses under elevated-tone conditions were inhibited by N omega-nitro-L-arginine methyl ester, suggesting that des-Arg9-bradykinin stimulates the release of nitric oxide, whereas meclofenamate and U-37883A, a nonsulfonylurea ATP-sensitive K+ channel antagonist, did not alter vasodilator responses to the B1 receptor agonist.	Meclofenamic Acid	204-217	kininogen 1	Homo sapiens	145-155
7858871-2	1994	The non-steroidal anti-inflammatory drugs (NSAIDs) indomethacin, 10 and 100 microM, piroxicam, 100 microM, and sodium meclofenamate, 1 and 100 microM, potentiated the lipopolysaccharide (LPS)-stimulated release of interleukin-1 (IL-1)-like activity from mouse peritoneal macrophages.	Meclofenamic Acid	111-131	interleukin 1 complex	Mus musculus	214-227
7858871-2	1994	The non-steroidal anti-inflammatory drugs (NSAIDs) indomethacin, 10 and 100 microM, piroxicam, 100 microM, and sodium meclofenamate, 1 and 100 microM, potentiated the lipopolysaccharide (LPS)-stimulated release of interleukin-1 (IL-1)-like activity from mouse peritoneal macrophages.	Meclofenamic Acid	111-131	interleukin 1 complex	Mus musculus	229-233
7858871-8	1994	The potentiation of LPS-stimulated release of IL-1-like activity produced by indomethacin, 100 microM, piroxicam, 100 microM, or sodium meclofenamate, 10 microM, was inhibited by prostaglandin E2, (PGE2) 10 ng ml-1.	Meclofenamic Acid	129-149	interleukin 1 complex	Mus musculus	46-50
7858871-10	1994	Aspirin, 100 microM, indomethacin, 100 nM to 10 microM, piroxicam, 1 to 100 microM, and sodium meclofenamate, 10 nM, all potentiated cell-associated IL-1-like activity in LPS- stimulated macrophages.	Meclofenamic Acid	88-108	interleukin 1 complex	Mus musculus	149-153
7858871-13	1994	Exogenous PGE2, 2 to 30 ng ml-1, inhibited the cell-accumulation of IL-1-like activity stimulated by LPS in the presence of indomethacin, 1 microM, or sodium meclofenamate, 0.1 microM.	Meclofenamic Acid	151-171	interleukin 1 complex	Mus musculus	68-72
7965814-6	1994	Indomethacin, flurbiprofen, meclofenamate and diclofenac, but not ibuprofen, piroxicam or phenylbutazone, caused time-dependent inhibition of both hPGHS-1 and -2 in vitro.	Meclofenamic Acid	28-41	prostaglandin-endoperoxide synthase 1	Homo sapiens	147-161
7965814-7	1994	For cells pretreated with flurbiprofen or meclofenamate, hPGHS-2 activities, but not hPGHS-1 activities, were recovered relatively rapidly; with indomethacin, recoveries of hPGHS-1 and hPGHS-2 activities were both slow.	Meclofenamic Acid	42-55	prostaglandin-endoperoxide synthase 2	Homo sapiens	57-64
7965814-7	1994	For cells pretreated with flurbiprofen or meclofenamate, hPGHS-2 activities, but not hPGHS-1 activities, were recovered relatively rapidly; with indomethacin, recoveries of hPGHS-1 and hPGHS-2 activities were both slow.	Meclofenamic Acid	42-55	prostaglandin-endoperoxide synthase 1	Homo sapiens	85-92
7965814-7	1994	For cells pretreated with flurbiprofen or meclofenamate, hPGHS-2 activities, but not hPGHS-1 activities, were recovered relatively rapidly; with indomethacin, recoveries of hPGHS-1 and hPGHS-2 activities were both slow.	Meclofenamic Acid	42-55	prostaglandin-endoperoxide synthase 1	Homo sapiens	173-180
7965814-7	1994	For cells pretreated with flurbiprofen or meclofenamate, hPGHS-2 activities, but not hPGHS-1 activities, were recovered relatively rapidly; with indomethacin, recoveries of hPGHS-1 and hPGHS-2 activities were both slow.	Meclofenamic Acid	42-55	prostaglandin-endoperoxide synthase 2	Homo sapiens	185-192
7808838-5	1994	In juvenile sheep, the increase in resting pulmonary arterial pressure produced by ET-1 was inhibited by meclofenamic acid, an inhibitor of prostaglandin synthesis (40.3 +/- 9.9% versus 2.3 +/- 4.7%, p < 0.05); during pulmonary hypertension, the decrease in pulmonary arterial pressure produced by ET-1 was inhibited by N omega-nitro-L-arginine, an inhibitor of endothelium-derived nitric oxide synthesis (21.4 +/- 10.7% versus 8.0 +/- 3.6%, p < 0.05) and by glybenclamide, an ATP-dependent potassium-channel blocker (18.8 +/- 8.4% versus 4.0 +/- 4.4%, p < 0.05).	Meclofenamic Acid	105-122	EDN1	Ovis aries	83-87
7808838-5	1994	In juvenile sheep, the increase in resting pulmonary arterial pressure produced by ET-1 was inhibited by meclofenamic acid, an inhibitor of prostaglandin synthesis (40.3 +/- 9.9% versus 2.3 +/- 4.7%, p < 0.05); during pulmonary hypertension, the decrease in pulmonary arterial pressure produced by ET-1 was inhibited by N omega-nitro-L-arginine, an inhibitor of endothelium-derived nitric oxide synthesis (21.4 +/- 10.7% versus 8.0 +/- 3.6%, p < 0.05) and by glybenclamide, an ATP-dependent potassium-channel blocker (18.8 +/- 8.4% versus 4.0 +/- 4.4%, p < 0.05).	Meclofenamic Acid	105-122	EDN1	Ovis aries	301-305
8279573-4	1993	The vasodilator responses to ET-1 and ET-3 were potentiated by the cyclooxygenase blocker meclofenamate (3 x 10(-6) M) or by the thromboxane synthetase inhibitor R-68070.	Meclofenamic Acid	90-103	endothelin 1	Rattus norvegicus	29-42
7919134-4	1994	When Bk was added to cocultures in the presence of meclofenamate (10(-5) M), Isc decreased from 62 +/- 12 to 44.5 +/- 7 muA/cm2, not significantly different from that in the absence of meclofenamate.	Meclofenamic Acid	51-64	kininogen 1	Homo sapiens	5-7
7919134-4	1994	When Bk was added to cocultures in the presence of meclofenamate (10(-5) M), Isc decreased from 62 +/- 12 to 44.5 +/- 7 muA/cm2, not significantly different from that in the absence of meclofenamate.	Meclofenamic Acid	185-198	kininogen 1	Homo sapiens	5-7
8127005-5	1994	Cyclooxygenase inhibition by indomethacin and meclofenamate abrogated the inhibitory effects of both IL-1 beta and IL-6.	Meclofenamic Acid	46-59	interleukin 1 beta	Rattus norvegicus	101-110
8127005-5	1994	Cyclooxygenase inhibition by indomethacin and meclofenamate abrogated the inhibitory effects of both IL-1 beta and IL-6.	Meclofenamic Acid	46-59	interleukin 6	Rattus norvegicus	115-119
8279573-5	1993	In meclofenamate-treated lungs, the vasodilator responses to ET-1 and ET-3 remained unaffected by the inhibitor of nitric oxide synthesis, NG-monomethyl-L-arginine (5 x 10(-4) M) or by the guanylate cyclase inhibitor, methylene blue (10(-4) M).	Meclofenamic Acid	3-16	endothelin 1	Rattus norvegicus	61-74
8508535-4	1993	However, in the arteries from the vitamin E-deprived rats, this response was potentiated in the presence of a cyclooxygenase inhibitor (1 microM meclofenamate; EC50, 0.035 +/- 0.003 versus 0.057 +/- 0.006 microM; P < .05) or thromboxane A2/prostaglandin H2 receptor blocker (1 microM SQ 29548; EC50 0.029 +/- 0.002 versus 0.057 +/- 0.006 microM; P < .05) but had no effect on the arteries from the control rats.	Meclofenamic Acid	145-158	UDP glucuronosyltransferase 1 family, polypeptide A7C	Rattus norvegicus	240-276
8365356-3	1993	Using an isolated perfused rat heart preparation, cyclooxygenase inhibition by indomethacin or meclofenamic acid (10 microM for each) significantly attenuated the rise in ANF associated with PAF administration (2.5 nmol).	Meclofenamic Acid	95-112	natriuretic peptide A	Rattus norvegicus	171-174
8238420-6	1993	The decrease in pulmonary arterial pressure produced by ET-1 (250 ng/kg) was attenuated by N omega-nitro-L-arginine (an inhibitor of endothelium-derived nitric oxide synthesis, 23.7 +/- 3.4 vs. 12.5 +/- 4.7%; P < 0.05) and by glibenclamide (an ATP-gated potassium-channel blocker, 25.2 +/- 5.0 vs. 9.6 +/- 5.3%; P < 0.05) but not by meclofenamic acid (an inhibitor of prostaglandin synthesis).	Meclofenamic Acid	339-356	EDN1	Ovis aries	56-60
1397474-7	1992	Meclofenamate significantly reduced plasma levels of stable metabolites of prostaglandin E2 as well as the growth hormone to growth releasing hormone, suggesting that the GRH effect on GH was at least partly under prostaglandin E2 control.	Meclofenamic Acid	0-13	growth hormone 1	Homo sapiens	107-121
8447442-6	1993	The cyclooxygenase inhibitor, meclofenamate, enhanced the effect of both BK and AVP on VSMC tone, as assessed by shape change, by a comparable degree.	Meclofenamic Acid	30-43	kininogen 1	Homo sapiens	73-75
8442433-4	1993	The stimulatory actions of TNF-alpha and TNF-beta on PGE2 formation was maximal at 12 h. Indomethacin, flurbiprofen, and meclofenamic acid, three structurally unrelated nonsteroidal antiinflammatory drugs, abolished PGE2 biosynthesis induced by TNF-alpha and TNF-beta (100 ng/ml).	Meclofenamic Acid	121-138	tumor necrosis factor	Mus musculus	27-36
8442433-4	1993	The stimulatory actions of TNF-alpha and TNF-beta on PGE2 formation was maximal at 12 h. Indomethacin, flurbiprofen, and meclofenamic acid, three structurally unrelated nonsteroidal antiinflammatory drugs, abolished PGE2 biosynthesis induced by TNF-alpha and TNF-beta (100 ng/ml).	Meclofenamic Acid	121-138	lymphotoxin A	Mus musculus	41-49
8442433-5	1993	The 45Ca release stimulated by TNF-alpha and TNF-beta (100 ng/ml), however, was only slightly reduced by indomethacin, flurbiprofen, and meclofenamic acid.	Meclofenamic Acid	137-154	tumor necrosis factor	Mus musculus	31-40
8454631-4	1993	Among common NSAIDs tested, indomethacin, sulindac sulfide, and piroxicam preferentially inhibited PGH synthase-1; ibuprofen, flurbiprofen, and meclofenamate inhibited both enzymes with comparable potencies; and 6-methoxy-2-naphthylacetic acid preferentially inhibited PGH synthase-2.	Meclofenamic Acid	144-157	prostaglandin-endoperoxide synthase 2	Mus musculus	269-283
1397474-7	1992	Meclofenamate significantly reduced plasma levels of stable metabolites of prostaglandin E2 as well as the growth hormone to growth releasing hormone, suggesting that the GRH effect on GH was at least partly under prostaglandin E2 control.	Meclofenamic Acid	0-13	gonadotropin releasing hormone 1	Homo sapiens	171-174
1539679-5	1992	Prior treatment of the cells in culture with the cyclooxygenase inhibitor, sodium meclofenamate (4 microM), markedly reduced the relaxant effect of the conditioned buffer, whereas prior treatment with MK-886, an inhibitor of 5-lipoxygenase, did not alter relaxant activity.	Meclofenamic Acid	75-95	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	49-63
1565180-5	1992	NSAIDs such as aspirin, indomethacin, meclofenamate and others may promote POD by blocking this prostaglandin pathway while promoting the cytochrome P450 monooxygenase pathway which may produce vasodilator, diuretic and natriuretic paracrine hormones.	Meclofenamic Acid	38-51	cytochrome P450, family 2, subfamily j, polypeptide 3	Rattus norvegicus	138-167
1781802-1	1991	The purpose of the present study, which was performed in anaesthetized rats, was to clarify whether the nonsteroidal anti-inflammatory drugs (NSAIDs) indomethacin and meclofenamate interact with the diuretic action of the new loop diuretic azosemide (Luret, CAS-27589-33-9).	Meclofenamic Acid	167-180	BCAR1 scaffold protein, Cas family member	Rattus norvegicus	258-261
1716063-7	1991	After preincubation with cyclooxygenase inhibitor meclofenamate (10(-6) M), ANG II (5 x 10(-7) M) resulted in a significantly higher uptake of IgG complexes compared with uptake by MC treated with ANG II alone (P less than 0.05).	Meclofenamic Acid	50-63	angiotensinogen	Rattus norvegicus	76-82
1716063-7	1991	After preincubation with cyclooxygenase inhibitor meclofenamate (10(-6) M), ANG II (5 x 10(-7) M) resulted in a significantly higher uptake of IgG complexes compared with uptake by MC treated with ANG II alone (P less than 0.05).	Meclofenamic Acid	50-63	angiotensinogen	Rattus norvegicus	197-203
1833368-3	1991	Airway responses to ET-1 were decreased significantly by sodium meclofenamate, a cyclooxygenase inhibitor, and by SKF 96148, a thromboxane receptor blocking agent.	Meclofenamic Acid	57-77	endothelin 1	Felis catus	20-24
1833368-6	1991	Bronchoconstrictor responses to ET-2, ET-3, and S6b were also decreased significantly by meclofenamate and by thromboxane receptor blocking agents.	Meclofenamic Acid	89-102	endothelin 2	Felis catus	32-36
35530301-0	2022	Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer.	Meclofenamic Acid	0-17	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	67-99
1725380-2	1991	In isolated control lung preparations studied during conditions of increased tone by U46619 (50 pmol/min) and treated with meclofenamate (3 microM), low doses of ET-1 (30 and 100 pM) reduced the pressor response to U46619 by 58 +/- 5% (p less than 0.01).	Meclofenamic Acid	123-136	endothelin 1	Rattus norvegicus	162-166
2104586-6	1990	A cyclooxygenase (CO) blocker, meclofenamate (M), which does not significantly alter basal renin release, attenuated the TNF- and rhIL-1 beta-induced renin secretion [TNF (20 U/ml), 132 +/- 11%; TNF plus M (5 X 10(-5) M), 100 +/- 3% (P less than 0.01); rhIL-1 beta (10 U/ml), 135 +/- 9%; rhIL-1 beta plus M, 105 +/- 10% (P less than 0.05)].	Meclofenamic Acid	31-44	tumor necrosis factor	Homo sapiens	121-124
2104586-6	1990	A cyclooxygenase (CO) blocker, meclofenamate (M), which does not significantly alter basal renin release, attenuated the TNF- and rhIL-1 beta-induced renin secretion [TNF (20 U/ml), 132 +/- 11%; TNF plus M (5 X 10(-5) M), 100 +/- 3% (P less than 0.01); rhIL-1 beta (10 U/ml), 135 +/- 9%; rhIL-1 beta plus M, 105 +/- 10% (P less than 0.05)].	Meclofenamic Acid	31-44	renin	Rattus norvegicus	150-155
2104586-6	1990	A cyclooxygenase (CO) blocker, meclofenamate (M), which does not significantly alter basal renin release, attenuated the TNF- and rhIL-1 beta-induced renin secretion [TNF (20 U/ml), 132 +/- 11%; TNF plus M (5 X 10(-5) M), 100 +/- 3% (P less than 0.01); rhIL-1 beta (10 U/ml), 135 +/- 9%; rhIL-1 beta plus M, 105 +/- 10% (P less than 0.05)].	Meclofenamic Acid	31-44	tumor necrosis factor	Homo sapiens	167-170
2104586-6	1990	A cyclooxygenase (CO) blocker, meclofenamate (M), which does not significantly alter basal renin release, attenuated the TNF- and rhIL-1 beta-induced renin secretion [TNF (20 U/ml), 132 +/- 11%; TNF plus M (5 X 10(-5) M), 100 +/- 3% (P less than 0.01); rhIL-1 beta (10 U/ml), 135 +/- 9%; rhIL-1 beta plus M, 105 +/- 10% (P less than 0.05)].	Meclofenamic Acid	31-44	tumor necrosis factor	Homo sapiens	167-170
2073934-5	1990	This vasopressin response was almost completely prevented by prior icv meclofenamate, a cyclooxygenase inhibitor, and the blood pressure response was attenuated.	Meclofenamic Acid	71-84	arginine vasopressin	Rattus norvegicus	5-16
2035656-6	1991	Changes in plasma and renal tissue renin on meclofenamate treatment were similar to those observed on 6% protein diet.	Meclofenamic Acid	44-57	renin	Rattus norvegicus	35-40
2035656-7	1991	Both protein restriction and meclofenamate administration increased the glomerular ANG II receptor number, while the receptor affinity was unchanged.	Meclofenamic Acid	29-42	angiotensinogen	Rattus norvegicus	83-89
2043304-1	1991	Intrarenal infusions of 5 ng/kg/min bradykinin (BK) in 5 mg/kg intravenous bolus meclofenamate-treated anesthetized dogs significantly increased renal blood flow, diuresis, natriuresis, and kaliuresis.	Meclofenamic Acid	81-94	kininogen 1	Canis lupus familiaris	36-46
2043304-1	1991	Intrarenal infusions of 5 ng/kg/min bradykinin (BK) in 5 mg/kg intravenous bolus meclofenamate-treated anesthetized dogs significantly increased renal blood flow, diuresis, natriuresis, and kaliuresis.	Meclofenamic Acid	81-94	kininogen 1	Canis lupus familiaris	48-50
2043304-6	1991	It is concluded that the renal vasodilatory and excretory responses to intrarenal BK in meclofenamate-treated dogs are largely dependent on endothelium-derived nitric oxide.	Meclofenamic Acid	88-101	kininogen 1	Canis lupus familiaris	82-84
2231411-6	1990	However, melittin-stimulated renin secretion is independent of melittin-stimulated phospholipase A2 activity, arachidonic acid release, and PG synthesis, since 20 microM-quinacrine (a phospholipase A2 antagonist) and 50 microM-meclofenamate (a cyclooxygenase antagonist) antagonized basal and melittin-stimulated PGE2 synthesis but had no effects on basal or melittin-stimulated renin secretion.	Meclofenamic Acid	226-240	renin	Rattus norvegicus	29-34
2307110-7	1990	Mec elicited a dose-dependent reduction (P less than 0.01) in control activity (incubated with 50 microM GTP), as well as inhibiting hCG- and PG-stimulated activity.	Meclofenamic Acid	0-3	chorionic gonadotropin subunit beta 5	Homo sapiens	133-136
2307110-8	1990	The presence of 100 microM Mec suppressed (P less than 0.01) hCG-, PGE2- and PGI2-stimulated activity to control levels, but had no effect on activity stimulated by GMP-P(NH)P or forskolin.	Meclofenamic Acid	27-30	chorionic gonadotropin subunit beta 5	Homo sapiens	61-64
2307110-12	1990	The presence of 100 microM Mec reduced (P less than 0.01) basal P production by 62% and abolished (P less than 0.05) hCG-, PG-, and dbcAMP-induced stimulation.	Meclofenamic Acid	27-30	chorionic gonadotropin subunit beta 5	Homo sapiens	117-120
34102854-5	2021	Effect of intraperitoneal administration of meclofenamic acid (a FTO inhibitor) or microinjection of adeno-associated virus 5 (AAV5) expressing Cre into the thalamus of Ftofl/fl mice on the Coll IV microinjection-induced TLR4 (Toll-like receptor 4) upregulation and nociceptive hypersensitivity was examined.	Meclofenamic Acid	44-61	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	65-68
34102854-10	2021	Intraperitoneal injection of meclofenamic acid or adeno-associated virus-5 expressing Cre microinjection into Ftofl/fl mouse thalamus attenuated the Coll IV microinjection-induced TLR4 upregulation and tissue damage in the ipsilateral thalamus and development and maintenance of nociceptive hypersensitivities on the contralateral side.	Meclofenamic Acid	29-46	toll-like receptor 4	Mus musculus	180-184
35530301-0	2022	Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer.	Meclofenamic Acid	0-17	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	139-142
35530301-0	2022	Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer.	Meclofenamic Acid	0-17	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	161-166
35045869-0	2022	Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.	Meclofenamic Acid	20-33	O-6-methylguanine-DNA methyltransferase	Homo sapiens	49-53
35045869-5	2022	METHODS: In this study, combined MFA/TMZ therapy will be administered (orally) in patients with first relapse of MGMT-methylated glioblastoma.	Meclofenamic Acid	33-36	O-6-methylguanine-DNA methyltransferase	Homo sapiens	113-117
2508492-2	1989	Our specific objective was to characterize the effects of two chemically dissimilar inhibitors of the cyclooxygenase pathway, indomethacin and sodium meclofenamate, on the pulmonary vascular P/Q relationship measured in conscious and pentobarbital-anesthetized dogs.	Meclofenamic Acid	143-163	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	102-116
2802003-8	1989	When the PG synthesis inhibitor meclofenamate was given there was no change in the pressor response to ANG II in nonpregnant animals, but in pseudopregnant animals meclofenamate produced a significant increase in the pressor response to ANG II.	Meclofenamic Acid	32-45	angiotensinogen	Rattus norvegicus	237-243
34983657-10	2022	The selected NSAIDs caused a concentration-dependent inhibition of FAAH-1 activity with sulindac, carprofen and meclofenamate exhibiting the greatest potency.	Meclofenamic Acid	112-125	fatty acid amide hydrolase	Homo sapiens	67-73
34983657-11	2022	Michaelis-Menten analysis suggested the mode of inhibition of FAAH-1 hydrolysis of both oleamide and arachidonamide by meclofenamate and indomethacin to be non-competitive in nature.	Meclofenamic Acid	119-132	fatty acid amide hydrolase	Homo sapiens	62-68
2802003-8	1989	When the PG synthesis inhibitor meclofenamate was given there was no change in the pressor response to ANG II in nonpregnant animals, but in pseudopregnant animals meclofenamate produced a significant increase in the pressor response to ANG II.	Meclofenamic Acid	164-177	angiotensinogen	Rattus norvegicus	237-243
2508492-6	1989	Cyclooxygenase pathway inhibition with either indomethacin (5 mg/kg iv) or meclofenamate (2.5 mg/kg iv) resulted in active, flow-independent pulmonary vasoconstriction (P less than 0.01) in both conscious and pentobarbital-anesthetized dogs.	Meclofenamic Acid	75-88	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	0-14
2802003-11	1989	Like in pregnancy, the pressor response to ANG II was increased after meclofenamate in pseudopregnancy.	Meclofenamic Acid	70-83	angiotensinogen	Rattus norvegicus	43-49
2547868-4	1989	The renin release stimulated by theophylline was completely abolished by indomethacin and meclofenamate.	Meclofenamic Acid	90-103	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	4-9
2546189-5	1989	Meclofenamate, an inhibitor of cyclooxygenase, counteracted both the blunting of hypoxic vasoconstriction and the increased level of 6-keto-PGF1 alpha.	Meclofenamic Acid	0-13	prostaglandin F synthase 2	Bos taurus	140-144
2498384-6	1989	T4; n = 3; P less than 0.001], while mefenamic acid, diflunisal, and meclofenamic acid were 20-26% as potent as T4 in their interaction with TTR.	Meclofenamic Acid	69-86	transthyretin	Homo sapiens	141-144
2545509-8	1989	We also conducted competitive receptor binding assays for tolmetin, meclofenamate and ibuprofen on the FMLP receptor.	Meclofenamic Acid	68-81	formyl peptide receptor 1	Homo sapiens	103-116
2545509-10	1989	All three NSAID inhibited FMLP binding in a dose dependent manner with the potency order being meclofenamate greater than ibuprofen greater than tolmetin.	Meclofenamic Acid	95-108	formyl peptide receptor 1	Homo sapiens	26-30
2847557-5	1988	Cyclooxygenase inhibition alone (either indomethacin or sodium meclofenamate) resulted in active, nonflow-dependent pulmonary vasoconstriction.	Meclofenamic Acid	56-76	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	0-14
3142275-3	1988	Cyclooxygenase inhibition (COI) was induced by 40 microM indomethacin (n = 4) or 45 microM meclofenamate (n = 4) before 5-HT infusion in a second group (5-HTCOI; n = 8).	Meclofenamic Acid	91-104	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	0-14
3340625-0	1988	Potentiated vasoconstrictor response to vasopressin following meclofenamate in conscious rats.	Meclofenamic Acid	62-75	arginine vasopressin	Rattus norvegicus	40-51
2895793-3	1988	Synthesis of these products and growth and expression of Thy-1 and Lyt-1 Ag were inhibited by culture of fetal thymic lobes with indomethacin, a cyclooxygenase inhibitor, as well as meclofenamate and eicosatetraynoic acid, inhibitors of cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism.	Meclofenamic Acid	182-195	Thy-1 cell surface antigen	Homo sapiens	57-62
3126818-9	1988	The prostaglandin synthetase inhibitors indomethacin, meclofenamic acid and naproxen and 5,8,11,14-eicosatetraynoic acid reduced 45Ca release from thrombin-stimulated calvaria.	Meclofenamic Acid	54-71	coagulation factor II	Mus musculus	147-155
3270330-5	1988	Both indomethacin and meclofenamate abolished the inhibitory effects of secretin on gastric acid secretion.	Meclofenamic Acid	22-35	SCT	Canis lupus familiaris	72-80
2840395-6	1988	Indomethacin and meclofenamate (10(-8) to 2 X 10(-6) M) added to the perfusion medium suppressed immunoreactive Ang I and II release to similar extents in a dose-dependent manner (p less than 0.001); the maximal percent inhibition of immunoreactive Ang II release evoked by these inhibitors (2 X 10(-6) M) was 60 +/- 6% (p less than 0.001) for indomethacin and 50 +/- 4% (p less than 0.001) for meclofenamate.	Meclofenamic Acid	17-30	angiotensinogen	Rattus norvegicus	112-124
2840395-6	1988	Indomethacin and meclofenamate (10(-8) to 2 X 10(-6) M) added to the perfusion medium suppressed immunoreactive Ang I and II release to similar extents in a dose-dependent manner (p less than 0.001); the maximal percent inhibition of immunoreactive Ang II release evoked by these inhibitors (2 X 10(-6) M) was 60 +/- 6% (p less than 0.001) for indomethacin and 50 +/- 4% (p less than 0.001) for meclofenamate.	Meclofenamic Acid	17-30	angiotensinogen	Rattus norvegicus	249-255
2840395-8	1988	There was a highly significant positive correlation between the released amount of immunoreactive Ang I and that of immunoreactive Ang II altered by indomethacin (r = 0.91), meclofenamate (r = 0.94), or propranolol administration (r = 0.90).	Meclofenamic Acid	174-187	angiotensinogen	Rattus norvegicus	131-137
3014892-11	1986	Meclofenamate (M) inhibits prostaglandin synthesis, reduces plasma renin activity, and enhances the pressor response to infused Ang II in pregnant rabbits.	Meclofenamic Acid	0-13	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	67-72
2827506-10	1987	In contrast, meclofenamate worsened the renal hemodynamic effects of PAF.	Meclofenamic Acid	13-26	PCNA clamp associated factor	Rattus norvegicus	69-72
3628982-4	1987	Infusion of sodium meclofenamate for 18 hours significantly (P less than 0.005) reduced the effect of E2 beta administered simultaneously.	Meclofenamic Acid	12-32	dihydrolipoamide branched chain transacylase E2	Homo sapiens	102-109
3593436-4	1987	Bradykinin-stimulated resorption was inhibited by calcitonin, an increased concentration of phosphate in the culture medium, hydrocortisone, dexamethasone, indomethacin, meclofenamic acid, naproxen, and 5, 8, 11, 14-eicosatetraenoic acid.	Meclofenamic Acid	170-187	kininogen 1	Bos taurus	0-10
3109872-8	1987	Angiotensin II produces a concentration-dependent contraction of isolated rat glomeruli or mesangial cells which is potentiated by pretreatment with indomethacin or meclofenamate.	Meclofenamic Acid	165-178	angiotensinogen	Rattus norvegicus	0-14
3524265-12	1986	Acute inhibition of prostaglandin synthesis with meclofenamate restored the pressor response to ANG II in HP to that in LP.	Meclofenamic Acid	49-62	angiotensinogen	Rattus norvegicus	96-102
3083482-4	1986	Cyclo-oxygenase was inhibited by infusion of meclofenamate (60 micrograms X min-1) which consistently abolished the vasodilator responses to arachidonic acid added to the donor.	Meclofenamic Acid	45-58	CD59 molecule (CD59 blood group)	Homo sapiens	76-81
3084759-4	1986	However, in dogs pretreated with indomethacin (5 mg/kg) or sodium meclofenamate (3 mg/kg), inhibitors of cyclooxygenase, hydralazine injection resulted in an increase in renal artery blood flow of only 44 +/- 5.3 ml/min (19 +/- 2.7%) from 235 +/- 23 ml/min, an increase significantly different from that in control dogs (P less than .05).	Meclofenamic Acid	59-79	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	105-119
2936254-4	1986	Inhibition of glomerular PG synthesis with indomethacin or meclofenamate potentiated the threshold response of ANG II to reduce GPSA.	Meclofenamic Acid	59-72	angiotensinogen	Rattus norvegicus	111-117
3159511-11	1985	These data indicate that the combination of endothelial injury and cyclooxygenase inhibition with indomethacin or meclofenamate results in proximal coronary artery vasoconstriction.	Meclofenamic Acid	114-127	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	67-81
3931483-4	1985	Since it has been demonstrated recently that cyclooxygenase inhibitors (meclofenamic acid) abrogate the inhibition by colchicine of vasopressin-stimulated water flow, we tested by stereological criteria the hypothesis that colchicine in the presence of meclofenamic acid does not prevent the polymerization of tubulin.	Meclofenamic Acid	72-89	arginine vasopressin	Homo sapiens	132-143
3925124-9	1985	), the effect of indomethacin or sodium meclofenamate to attentuate bradykinin-induced vasodilation was reduced.	Meclofenamic Acid	33-53	kininogen 1	Canis lupus familiaris	68-78
3920919-4	1985	In rings of femoral and pulmonary vein contracted with norepinephrine, arachidonic acid produced a concentration-dependent increase in tension that was eliminated by removal of the endothelium or by treatment with the inhibitors of cyclooxygenase (indomethacin, meclofenamate, or acetylsalicyclic acid).	Meclofenamic Acid	262-275	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	232-246
6345360-6	1983	The pressor effect of AII increased in pregnant rabbits after the administration of meclofenamate and parturition but was not changed by volume expansion.	Meclofenamic Acid	84-97	NLR family pyrin domain containing 3	Homo sapiens	22-25
2409021-4	1985	When FMLP was used to stimulate histamine release the order of potency (IC50) changed: meclofenamate = FPL 55712 = proxicromil less than CI-922 less than NDGA = BW755c less than indomethacin less than isamoxole = phenidone.	Meclofenamic Acid	87-100	formyl peptide receptor 1	Homo sapiens	5-9
2409021-5	1985	The inhibition of FMLP-induced histamine release by FPL 55712, meclofenamate and indomethacin in the absence of inhibition (or even enhancement) of histamine release by the IgE mechanism suggests that different pathways of activation and/or control are critical in the release process when different stimuli are used to activate basophils.	Meclofenamic Acid	63-76	formyl peptide receptor 1	Homo sapiens	18-22
6377924-5	1984	Inhibition of prostaglandin synthesis with meclofenamate increased the pressor response to angiotensin II toward normal in pregnant animals.	Meclofenamic Acid	43-56	angiotensinogen	Rattus norvegicus	91-105
6377924-7	1984	Furthermore, meclofenamate increased the pressor response to norepinephrine and vasopressin in pregnant rats.	Meclofenamic Acid	13-26	arginine vasopressin	Rattus norvegicus	80-91
6626566-9	1983	Indomethacin, sodium meclofenamate and mepacrine, but not dexamethasone or aspirin, inhibited the sperm phospholipase A2 activity.	Meclofenamic Acid	14-34	phospholipase A2, group IB, pancreas	Mus musculus	104-120
6648060-8	1983	In a further 5 dogs pretreated with meclofenamate (2 mg/kg IV) the PVR increased from 3.7 +/- 0.4 to 7.5 +/- 0.4 with hypoxia prior to IV ZAP and from 4.4 +/- 0.5 to 6.5 +/- 0.6 after ZAP.	Meclofenamic Acid	36-49	zinc finger CCCH-type containing, antiviral 1	Homo sapiens	138-141
6648060-8	1983	In a further 5 dogs pretreated with meclofenamate (2 mg/kg IV) the PVR increased from 3.7 +/- 0.4 to 7.5 +/- 0.4 with hypoxia prior to IV ZAP and from 4.4 +/- 0.5 to 6.5 +/- 0.6 after ZAP.	Meclofenamic Acid	36-49	zinc finger CCCH-type containing, antiviral 1	Homo sapiens	184-187
6648060-10	1983	The protection of the hypoxic pressor response by meclofenamate suggests that the ZAP inhibition (like endotoxin inhibition) may involve dilator prostaglandin-like substances.	Meclofenamic Acid	50-63	zinc finger CCCH-type containing, antiviral 1	Homo sapiens	82-85
6383082-0	1984	Effects of meclofenamate on the renin response to aortic constriction in the rat.	Meclofenamic Acid	11-24	renin	Rattus norvegicus	32-37
6383842-3	1984	Prostaglandin synthesis inhibition with meclofenamate (5 mg/kg) or indomethacin (5 mg/kg) significantly enhanced the pressor response for AII at infusion rates of 0.10, 0.30 and 1.0 microgram/kg per min (P less than 0.05) in rats previously on a low sodium intake but had no effect in rats previously on a high sodium intake.	Meclofenamic Acid	40-53	angiotensinogen	Rattus norvegicus	138-141
6360171-2	1983	The addition of either indomethacin or meclofenamate completely blocked this effect of insulin.	Meclofenamic Acid	39-52	insulin	Oryctolagus cuniculus	87-94
6344655-5	1983	In animals pretreated with either indomethacin or meclofenamate, the ability of secretin to produce an initial vasoconstriction was abolished and the subsequent vasodilator component of the response as well as caerulein-induced vasodilation were reduced in duration.	Meclofenamic Acid	50-63	SCT	Canis lupus familiaris	80-88
6260459-3	1981	To investigate the role of PGs in the control of isoproterenol-induced renin release, we studied the effect of two inhibitors of PG synthesis, indomethacin and meclofenamate, on the renin release stimulated by isoproterenol and dibutyryl cAMP.	Meclofenamic Acid	160-173	renin	Rattus norvegicus	182-187
6301285-4	1983	Indomethacin or meclofenamate, prostaglandin synthesis inhibitors, did not affect the decrease in urinary sodium excretion but attenuated the increase in renin secretion rate, from 1,523 +/- 416 to 866 +/- 413 ng/min (51 +/- 18%).	Meclofenamic Acid	16-29	renin	Canis lupus familiaris	154-159
6165819-5	1981	Pretreatment of dogs with an inhibitor of PG synthesis, sodium meclofenamate (5 mg/kg), abolished the inhibitory effect of bradykinin on angiotensin II-induced renal vasoconstriction.	Meclofenamic Acid	56-76	kininogen 1	Canis lupus familiaris	123-133
6794096-7	1981	Meclofenamate (10(-7)M) pretreatment of strips subjected to dose-response studies using PGF2 alpha, PGE2, bradykinin (B K) and angiotensin II (AII) revealed a significant reduction in tension developed to both BK and AII.	Meclofenamic Acid	0-13	kininogen 1	Homo sapiens	106-116
6794096-7	1981	Meclofenamate (10(-7)M) pretreatment of strips subjected to dose-response studies using PGF2 alpha, PGE2, bradykinin (B K) and angiotensin II (AII) revealed a significant reduction in tension developed to both BK and AII.	Meclofenamic Acid	0-13	kininogen 1	Homo sapiens	118-121
6794096-7	1981	Meclofenamate (10(-7)M) pretreatment of strips subjected to dose-response studies using PGF2 alpha, PGE2, bradykinin (B K) and angiotensin II (AII) revealed a significant reduction in tension developed to both BK and AII.	Meclofenamic Acid	0-13	angiotensinogen	Homo sapiens	127-141
6794096-7	1981	Meclofenamate (10(-7)M) pretreatment of strips subjected to dose-response studies using PGF2 alpha, PGE2, bradykinin (B K) and angiotensin II (AII) revealed a significant reduction in tension developed to both BK and AII.	Meclofenamic Acid	0-13	angiotensinogen	Homo sapiens	143-146
6794096-7	1981	Meclofenamate (10(-7)M) pretreatment of strips subjected to dose-response studies using PGF2 alpha, PGE2, bradykinin (B K) and angiotensin II (AII) revealed a significant reduction in tension developed to both BK and AII.	Meclofenamic Acid	0-13	NLR family pyrin domain containing 3	Homo sapiens	210-220
6260459-6	1981	Isoproterenol (8 x 10(-7) M) increased renin and PGE2 release which was blocked by indomethacin (10(-4) M) and meclofenamate (10(-4) M).	Meclofenamic Acid	111-124	renin	Rattus norvegicus	39-44
7457608-4	1981	The AII-induced inhibition of water absorption can be abolished, and a net stimulation ensues after pretreatment of the animals with meclofenamate or indomethacin, suggesting that at high doses AII stimulates intestinal prostaglandin biosynthesis.	Meclofenamic Acid	133-146	angiotensinogen	Rattus norvegicus	194-197
7004211-9	1980	Treatment of glomeruli with 6.3 X 10(-6) M meclofenamate attenuated PGE2 synthesis and abolished renin release, but 1.2 X 10(-4) M propranolol had no effect on PG synthesis or the coincident release of renin.	Meclofenamic Acid	43-56	renin	Rattus norvegicus	97-102
6160349-6	1981	Release of the PGI2-like substance by angiotensin II was reduced after intravenous administration of indomethacin (2, 5, or 10 mg/kg), aspirin (100 mg/kg), aspirin (100 mg/kg), and meclofenamic acid (2 mg/kg), but was not completely eliminated by any of the above inhibitors.	Meclofenamic Acid	181-198	angiotensinogen	Rattus norvegicus	38-52
6991156-0	1980	Effects of indomethacin and meclofenamate on renin release and renal hemodynamic function during chronic sodium depletion in conscious dogs.	Meclofenamic Acid	28-41	renin	Canis lupus familiaris	45-50
7449252-6	1980	Pretreatment of the dogs with an inhibitor of prostaglandin synthesis, sodium meclofenamate (5 mg/kg), blunted the inhibitory action of bradykinin, but not that of prostaglandin E2, on renal vascular reactivity to angiotensin II and noradrenaline.	Meclofenamic Acid	71-91	kininogen 1	Canis lupus familiaris	136-146
6798201-6	1981	Indomethacin (8 mg/kg) or meclofenamic acid (10 mg/kg) inhibited the rise plasma renin activity produced by the decrease in renal perfusion pressure in this model, although a comparable decrease in urinary sodium excretion was achieved.	Meclofenamic Acid	26-43	renin	Canis lupus familiaris	81-86
522895-0	1979	Studies on the inhibitory effect of indomethacin and meclofenamate on the adrenalectomy-induced increase in plasma renin concentration.	Meclofenamic Acid	53-66	renin	Rattus norvegicus	115-120
6998061-5	1980	The thrombin-induced contractions were significantly inhibited by prostacyclin, meclofenamic acid, phenoxybenzamine and glycerol.	Meclofenamic Acid	80-97	coagulation factor II, thrombin	Homo sapiens	4-12
7397403-5	1980	Angiotensin II (25 nM) produced a 31 mm Hg increase in perfusion pressure in coronary arteries but indomethacin (20 muM) or sodium meclofenamate (75 muM) reduced this response to 11 and 14 mm Hg, respectively (p < 0.05).	Meclofenamic Acid	124-144	latexin	Homo sapiens	149-152
500824-1	1979	The effect of two prostaglandin synthesis inhibitors, indomethacin and meclofenamate, on angiotensin II (AII)- and III (AIII)-induced aldosterone release was studied in normal and sodium-depleted conscious rats and in adrenal capsular cell suspensions obtained from normal rats.	Meclofenamic Acid	71-84	angiotensinogen	Rattus norvegicus	89-103
500824-5	1979	In contrast, meclofenamate failed to alter basal serum levels of aldosterone or AII-stimulated aldosterone release but inhibited serum renin levels by 27% and the aldosterone-stimulating effect of AIII by 99%.	Meclofenamic Acid	13-26	renin	Rattus norvegicus	135-140
522895-2	1979	Seventy-two hours after adrenalectomy the inhibitors of prostaglandin biosynthesis indomethacin and meclofenamate diminished the plasma renin concentration by about 50%.	Meclofenamic Acid	100-113	renin	Rattus norvegicus	136-141
522895-4	1979	Indomethacin and meclofenamate fully retained their ability to reduce the plasma renin concentration when the renal sympathetic nerves or the macular densa cells of the kidneys no longer contributed to renin release.	Meclofenamic Acid	17-30	renin	Rattus norvegicus	81-86
522895-4	1979	Indomethacin and meclofenamate fully retained their ability to reduce the plasma renin concentration when the renal sympathetic nerves or the macular densa cells of the kidneys no longer contributed to renin release.	Meclofenamic Acid	17-30	renin	Rattus norvegicus	202-207
430427-0	1979	The effect of meclofenamate on the natriuretic and antinatriuretic actions of angiotensin II [proceedings].	Meclofenamic Acid	14-27	angiotensinogen	Homo sapiens	78-92
37256-5	1979	Another PG synthetase inhibitor, meclofenamate, was also effective in attenuating hydralazine-induced renin release, urinary PGE(2) and PGF(2alpha) excretion, and arachidonate hypotension.	Meclofenamic Acid	33-46	renin	Rattus norvegicus	102-107
420294-7	1979	In particular, an indomethacin- and meclofenamate-sensitive vasodilator (presumably prostaglandin) plays a role in antagonizing the effects of a simultaneously acting vasoconstrictor which, although not identified, displayed the functional properties of angiotensin II.	Meclofenamic Acid	36-49	angiotensinogen	Rattus norvegicus	254-268
120320-5	1979	Meclofenamate, another prostaglandin synthesis inhibitor, also blocked saralasin-induced renin release by 99% and 72% at the 10 and 30 mg/kg doses, respectively (p less than 0.001).	Meclofenamic Acid	0-13	renin	Rattus norvegicus	89-94
32680921-7	2020	The ethyl ester form of meclofenamic acid (MA2) inhibited FTO and enhanced the effect of the chemotherapy drug temozolomide on suppressing proliferation of glioma cells and negatively regulated the loop.	Meclofenamic Acid	24-41	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	58-61
33829413-3	2021	The present study sought to examine the effect of intrathecal administration of two specific FTO inhibitors, meclofenamic acid (MA) and N-CDPCB, on the development and maintenance of nociceptive hypersensitivities caused by unilateral L5 spinal nerve ligation (SNL) in rats.	Meclofenamic Acid	109-126	FTO, alpha-ketoglutarate dependent dioxygenase	Rattus norvegicus	93-96
33412003-5	2021	FTO has recently gained interest as a potential cancer target, and small molecule FTO inhibitors such as meclofenamic acid have been shown to prevent tumor progression in both acute myeloid leukemia and glioblastoma in vivo models.	Meclofenamic Acid	105-122	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	82-85
31578283-0	2019	Meclofenamic acid promotes cisplatin-induced acute kidney injury by inhibiting fat mass and obesity-associated protein-mediated m6A abrogation in RNA.	Meclofenamic Acid	0-17	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	79-118
29875633-3	2018	It has been proposed that epigenetic modifications are related to inner ear development and play a significant role in HC protection and HC regeneration; however, whether the m6A modification and the ethyl ester form of meclofenamic acid (MA2), which is a highly selective inhibitor of FTO (fatmass and obesity-associated enzyme, one of the primary human demethylases), can affect the process of HC apoptosis induced by ototoxic drugs remains largely unexplored.	Meclofenamic Acid	220-237	PNMA family member 2	Homo sapiens	239-242
30878890-4	2019	Regarding 15-LOX inhibitory activity, compounds belonging to aryl carboximidamide backbone 3b-e and 3g were the most potent with IC50 range of 1.77-4.91 nM comparing to meclofenamate sodium (IC50 = 5.64 microM).	Meclofenamic Acid	169-189	arachidonate 15-lipoxygenase	Homo sapiens	10-16
31333841-5	2019	Methods: Mouse GC-1 spg cells were treated with the ester form of meclofenamic acid (MA2) to inhibit the demethylase activity of FTO.	Meclofenamic Acid	66-83	PNMA family member 2	Homo sapiens	85-88
31333841-5	2019	Methods: Mouse GC-1 spg cells were treated with the ester form of meclofenamic acid (MA2) to inhibit the demethylase activity of FTO.	Meclofenamic Acid	66-83	fat mass and obesity associated	Mus musculus	129-132
30628061-6	2019	Cx43-deleted OECs exhibited features consistent with the loss of gap junctions including reduced membrane conductance, largely reduced sensitivity to the gap junction blocker meclofenamic acid and loss of dye coupling.	Meclofenamic Acid	175-192	gap junction protein, alpha 1	Mus musculus	0-4
29875633-3	2018	It has been proposed that epigenetic modifications are related to inner ear development and play a significant role in HC protection and HC regeneration; however, whether the m6A modification and the ethyl ester form of meclofenamic acid (MA2), which is a highly selective inhibitor of FTO (fatmass and obesity-associated enzyme, one of the primary human demethylases), can affect the process of HC apoptosis induced by ototoxic drugs remains largely unexplored.	Meclofenamic Acid	220-237	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	286-289
29875633-3	2018	It has been proposed that epigenetic modifications are related to inner ear development and play a significant role in HC protection and HC regeneration; however, whether the m6A modification and the ethyl ester form of meclofenamic acid (MA2), which is a highly selective inhibitor of FTO (fatmass and obesity-associated enzyme, one of the primary human demethylases), can affect the process of HC apoptosis induced by ototoxic drugs remains largely unexplored.	Meclofenamic Acid	220-237	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	291-328
29435052-0	2018	Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism.	Meclofenamic Acid	32-49	aldo-keto reductase family 1 member C3	Homo sapiens	134-140
29435052-13	2018	The combination of simvastatin and meclofenamic acid, an AKR1C3 inhibitor, further enhanced the inhibition of cell proliferation and migration compared with treatment with either drug alone.	Meclofenamic Acid	35-52	aldo-keto reductase family 1 member C3	Homo sapiens	57-63
29435052-14	2018	Furthermore, treatment with simvastatin attenuated insulin-like growth factor 1-induced Akt activation; however, the combination of simvastatin and meclofenamic acid further inhibited Akt activation.	Meclofenamic Acid	148-165	insulin like growth factor 1	Homo sapiens	51-79
29435052-14	2018	Furthermore, treatment with simvastatin attenuated insulin-like growth factor 1-induced Akt activation; however, the combination of simvastatin and meclofenamic acid further inhibited Akt activation.	Meclofenamic Acid	148-165	AKT serine/threonine kinase 1	Homo sapiens	184-187